Loading...

Εκπαιδευτικά προγράμματα

Καταχωρήθηκε: Πέμπτη 25 Ιούν 2020
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas
Καταχωρήθηκε: Τρίτη 23 Ιούν 2020
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas
Καταχωρήθηκε: Παρασκευή 12 Ιούν 2020
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka,Dr Vadratsikas
Καταχωρήθηκε: Τετάρτη 03 Ιούν 2020
Our institutional guidelines discussed Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Δευτέρα 25 Μάι 2020
The first successful trial in steroid refractory GVHD. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Τρίτη 12 Μάι 2020
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Τετάρτη 06 Μάι 2020
We discussed a case of CNS lymphoma and the diffrent HD regimens. we favour regimens with Rituxmab, Thiotepa and bu or AraC   R-Busulfan-thiotepa Rituximab -6 Busulfan 2 days -5, -4 Thiotepa 5 mg/kg days -4 and -3   (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5473-z)   Other regimens Regimen without Thiotepa BUCYE Busulfan 3.2 mg/kg days...
Καταχωρήθηκε: Τετάρτη 29 Απρ 2020
We discussed the current EBMT guidelines for COVID19. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Δευτέρα 27 Απρ 2020
The current Indications for HCT were discussed. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Τρίτη 14 Απρ 2020
This cohort analysis evaluates theincidence, risk factors and mortality of pre-engraftment blood-stream infections(BSIs) and ds-DNAviral infections (VIs) after HSCTwith post-transplant cyclophosphamide(PT-Cy) platform among different donor sourcesAllogeneic HSCT with PT-Cy showed a 32% incidence of pre-engraftment BSIsand donor type did not affect their occurrence·VIsare common in early...
Καταχωρήθηκε: Παρασκευή 10 Απρ 2020
Even at low doses, nivolumab maintenance after allo-SCT can cause serious immune-related toxicitiesWe report rapid, unexpected occurrences of grade 3/4 immune-related adverse events ·Nivolumab enhanced the graft-vs-tumor response but more studies are needed to improve tolerability Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Δευτέρα 06 Απρ 2020
An excellent overview. We discusssed the differences betwen current used flt3 inhibitors. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Πέμπτη 02 Απρ 2020
An article published in BMT suggest that PT/Cy-haplo recipients may  reconstitute CMV-specific T-cell immunity to the same extent as patients  undergoing HLA-matched allo-HSCT Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Τετάρτη 01 Απρ 2020
Results of the international MRC UKALLXII/ECOG E2993 trial. Out of the  1 752 patients who achieved CR, 11·7% underwent autologous and 40·6%  allogeneic transplant, while in CR1. Of the autologous patients, 43·2%  relapsed early and 3·4% relapsed late. However, among the allogeneic  patients, 13·2% relapsed early and only 1·3%...
Καταχωρήθηκε: Δευτέρα 30 Μάρ 2020
Excellent review. The most of the newly approved drugs are for pts >75  years. The "problems"  of the approval trials are discussed. AS the  authro points: Don’t trust the horse, Trojans. Whatever it is, I fearthe Greeks even  bearing gifts.)—Virgi Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou,...
Καταχωρήθηκε: Παρασκευή 20 Μάρ 2020
A combination of phenotypic and functional immune assays enables risk-stratification of patients with viral infections after transplantFunctional immune monitoring can help identify patients in need of additional antiviral intervention Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Παρασκευή 20 Μάρ 2020
A retrospective study, The combination of thiotepa, busulfan fludarabine (TBF) reduces the risk of relapse in patients with remission AML, as compared to myeloablative busulfan fludarabine (BUFLU)The effect is independt of donor type and GvHD prophylaxis. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Παρασκευή 20 Μάρ 2020
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Βρέθηκαν 241 αποτελέσματα. Σελίδα 1 από 13
Σελίδα [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] > >>
 

 

Τηλέφωνα Επικοινωνίας:

 

Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)

 

βρείτε μας στο χάρτη

 

Login / Sitemap

 

© Copyright 2015 - 2020 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας